A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.

Kaposi sarcoma (KS) risk is affected by perturbed immunity. Herein, we compared plasma from 15 human immunodeficiency virus (HIV)-negative classic KS cases to plasma from 29 matched controls, using a multiplex panel of immunity markers. Of 70 markers, CXCL10 (IP-10), sIL-1RII, sIL-2RA, and CCL3 (MIP-1A) were strongly and significantly associated with KS, after adjustment for age and smoking status. These and previous observations are consistent with a tumor-promoting role for these cytokines, particularly CXCL10, but the small sample size and case-control design preclude firm conclusions on KS risk or pathogenesis. Larger, well-designed prospective studies are needed to better assess the association of these markers with KS.

[1]  Takeshi Takahashi,et al.  Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens , 2012, Annals of Hematology.

[2]  J. Goedert,et al.  Differences in Kaposi sarcoma‐associated herpesvirus‐specific and herpesvirus‐non‐specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily , 2011, Cancer science.

[3]  J. P. McCoy,et al.  Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[4]  D. Whitby,et al.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. , 2011, Cancer letters.

[5]  J. Goedert,et al.  Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls , 2011, British Journal of Cancer.

[6]  J. Goedert,et al.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30 , 2010, Infectious Agents and Cancer.

[7]  Y. Oron,et al.  Kaposi's Sarcoma-Associated Herpesvirus-G Protein-Coupled Receptor-Expressing Endothelial Cells Exhibit Reduced Migration and Stimulated Chemotaxis by Chemokine Inverse Agonists , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  J. Goedert,et al.  Risk Factors for Classical Kaposi Sarcoma in a Population-based Case-control Study in Sicily , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  H. Alexander,et al.  Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .

[10]  J. Goedert,et al.  Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma , 2006, Cancer.

[11]  S. Steinberg,et al.  Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.

[12]  J. Goedert,et al.  Associations of Classic Kaposi Sarcoma with Common Variants in Genes that Modulate Host Immunity , 2006, Cancer Epidemiology Biomarkers & Prevention.

[13]  E. Terpos,et al.  Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myeloma , 2005, Leukemia & lymphoma.

[14]  D. Dittmer,et al.  Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. , 2000, Virology.

[15]  D. Trichopoulos,et al.  The role of immunosuppression and immune‐activation in classic Kaposi's sarcoma , 1999, International journal of cancer.